Cancer Management and Research
Volume 11, 2019 - Issue
Open access
61
Views
4
CrossRef citations to date
0
Altmetric
Original Research
Short-term benefit of neoadjuvant hormone therapy in patients with localized high-risk or limited progressive prostate cancer
Bing-Lei Ma1 Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, Beijing, People’s Republic of China;2 Beijing Key Laboratory of Urogenital Diseases (male), Molecular Diagnosis and Treatment Center, Beijing, People’s Republic of China
, Lin Yao1 Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, Beijing, People’s Republic of China;2 Beijing Key Laboratory of Urogenital Diseases (male), Molecular Diagnosis and Treatment Center, Beijing, People’s Republic of China
, Yu Fan1 Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, Beijing, People’s Republic of China;2 Beijing Key Laboratory of Urogenital Diseases (male), Molecular Diagnosis and Treatment Center, Beijing, People’s Republic of China
, Yu Wang1 Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, Beijing, People’s Republic of China;2 Beijing Key Laboratory of Urogenital Diseases (male), Molecular Diagnosis and Treatment Center, Beijing, People’s Republic of China
, Yi-Sen Meng1 Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, Beijing, People’s Republic of China;2 Beijing Key Laboratory of Urogenital Diseases (male), Molecular Diagnosis and Treatment Center, Beijing, People’s Republic of ChinaCorrespondence[email protected] [email protected]
, Qian Zhang1 Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, Beijing, People’s Republic of China;2 Beijing Key Laboratory of Urogenital Diseases (male), Molecular Diagnosis and Treatment Center, Beijing, People’s Republic of China
, Zhi-Song He1 Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, Beijing, People’s Republic of China;2 Beijing Key Laboratory of Urogenital Diseases (male), Molecular Diagnosis and Treatment Center, Beijing, People’s Republic of China
, Jie Jin1 Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, Beijing, People’s Republic of China;2 Beijing Key Laboratory of Urogenital Diseases (male), Molecular Diagnosis and Treatment Center, Beijing, People’s Republic of China
& Li-Qun Zhou1 Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, Beijing, People’s Republic of China;2 Beijing Key Laboratory of Urogenital Diseases (male), Molecular Diagnosis and Treatment Center, Beijing, People’s Republic of China
show all
Pages 4143-4151
|
Published online: 10 May 2019
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.